Mark Newman | Chief Scientific Officer
GeoVax Labs, Inc.

Mark Newman, Chief Scientific Officer, GeoVax Labs, Inc.

Dr. Newman has more than 30 years’ experience in the biotechnology sector serving in senior management roles at GeoVax (Atlanta, GA), PaxVax (San Diego, CA), Pharmexa (Horsholm, Denmark), Epimmune (San Diego, CA), Vaxcel (Atlanta, GA), Apollon (Philadelphia, PA) and Cambridge Biotech (Boston, MA) where he directed research, development and early-stage clinical testing of protein, peptide, plasmid DNA and viral vectored vaccines and multiple vaccine adjuvants. He participated with or directed teams responsible for the transition of 10 vaccine or vaccine-related products from the research stage to Phase 1 and 2 clinical testing. He also served as the primary scientific director for multiple corporate teams supporting due diligence, technology assessments, intellectual property review and portfolio management to support strategic planning, technology in-licensing and out-licensing, corporate partnering and mergers and acquisitions.

Dr. Newman has co-authored 110 scientific papers, reviews and book chapters during his professional career. He is a named co-inventor on multiple issued US and PCT patents, all related to vaccine technologies. He served as the Principal Investigator on multiple USA government and foundation grants and contracts and as a grant and contract review expert for 35 years for National Institutes of Health and the United States Department of Agriculture.

Dr. Newman is a graduate of the Ohio State University (B.Sc. and M.Sc.) and received his Ph.D. in Immunology from the John Curtin School of Medical Research, the Australian National University (Canberra, Australia). He completed four years post-doctoral training at Cornell University and the Uniformed Services University of Health Sciences under contract with the National Cancer Institute, National Institutes of Health. He also served four years as a full-time member of the Louisiana State University faculty at the School of Veterinary Medicine prior to joining the biotechnology industry in 1989.


Day 3 - Thursday 4th April @ 12:00

Vaccine induction of broadly-specific antibody and T-cell responses to combat SARS-CoV-2 variation

last published: 26/Feb/24 13:16 GMT

back to speakers